Zilmax® and Rumensin™ and Tylan™
Veterinary medicine · U.S. Food and Drug Administration, Center for Veterinary Medicine · United States
-
Animal drug application
141276 -
Animal drug product ID
232
What the source publishes
- Holder
- Intervet, Inc.
- Active ingredients
- Monensin Tylosin Phosphate Zilpaterol Hydrochloride
- Form
- Type A Medicated Article
- Routes
- Oral
- Supply regime
- VFD
Names this record is found by
Complete source data
{
"form": "Type A Medicated Article",
"name": "Zilmax® and Rumensin™ and Tylan™",
"holder": "Intervet, Inc.",
"routes": [
"Oral"
],
"smpcUrl": null,
"marketed": null,
"useDomain": "veterinary",
"leafletUrl": null,
"supplyRegime": "VFD",
"nativeProduct": {
"routes": [
"Oral"
],
"species": {
"Cattle:408": "Fed in confinement for slaughter"
},
"sortOrder": 0,
"withdrawals": [
"3 days prior to slaughter."
],
"doseFormName": "Type A Medicated Article",
"applicationId": null,
"specifications": "Type A medicated article containing 21.77 grams of zilpaterol hydrochloride per pound. Type A medicated article containing 20, 30, 45, 60, 80, or 90.7 grams of monensin per pound. Type A medicated article containing 40 or 100 grams of tylosin (as tylosin phosphate) per pound.",
"proprietaryName": "Zilmax® and Rumensin™ and Tylan™",
"proprietaryNameId": 232,
"statusDescription": "VFD"
},
"nativeSummary": {
"noohDate": null,
"publishDate": "2018-10-25",
"sponsorName": "Intervet, Inc.",
"applicationId": 185,
"applicationType": "N",
"proprietaryName": "Zilmax® and Rumensin™ and Tylan™\n",
"applicationNumber": 141276,
"activeIngredientName": "Monensin\nTylosin Phosphate\nZilpaterol Hydrochloride\n",
"applicationStatusCode": "A",
"applicationStatusValue": null,
"voluntaryWithdrawalDate": null
},
"targetSpecies": [
{
"code": "408",
"label": "Cattle",
"native": {
"key": "Cattle:408",
"population": "Fed in confinement for slaughter"
},
"sourceId": "us.fda.animal-drugs",
"population": "Fed in confinement for slaughter",
"canonicalId": "cattle",
"mappingStatus": "mapped",
"mappingVersion": 1
}
],
"informationUrl": "https://animaldrugsatfda.fda.gov/adafda/views/#/search",
"ingredientScope": "application-level; no product-specific composition inferred",
"nativePublishDate": "2018-10-25",
"sourceDisposition": "reviewed-veterinary-application-product",
"useDomainEvidence": {
"basis": "publisher-dataset-scope",
"field": "sourceId",
"value": "us.fda.animal-drugs",
"version": 1,
"sourceId": "us.fda.animal-drugs"
},
"withdrawalPeriods": [
{
"native": "3 days prior to slaughter.",
"status": "unparsed"
}
],
"patientEligibility": "not-assessed",
"nativeApplicationId": 185,
"targetSpeciesStatus": "reported",
"administrativeStatus": "unknown",
"prescriptionCategory": "unknown",
"activeIngredientsText": "Monensin\nTylosin Phosphate\nZilpaterol Hydrochloride\n",
"nativeApplicationType": "N",
"applicationIngredients": [
{
"activeIngredientName": "Zilpaterol Hydrochloride",
"activeIngredientTolerance": "<p>The tolerance for zilpaterol is 12 parts per billion (ppb) in cattle liver and 10 ppb in cattle muscle.</p>"
},
{
"activeIngredientName": "Monensin",
"activeIngredientTolerance": "<p>A tolerance of 0.05 part per million is established for negligible residues of monensin in the edible tissues of cattle and goats. A tolerance for residues of monensin in chickens, turkeys and quail is not needed.</p>"
},
{
"activeIngredientName": "Tylosin Phosphate",
"activeIngredientTolerance": "<p>Tolerances are established for residues of tylosin in edible products of animals as follows: a. Chickens and turkeys: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney. b. Cattle: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney. c. Swine: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney. d. Milk: 0.05 part per million (negligible residue). e. Eggs: 0.2 part per million (negligible residue).</p>"
}
],
"nativeApplicationNumber": 141276,
"nativeProprietaryNameId": 232,
"restrictionObservations": [
{
"indicationText": "For increased rate of weight gain, improved feed efficiency, increased carcass leanness, prevention and control of coccidiosis due to <i>Eimeria bovis</i> and <i>E. zuernii</i>, and reduction of incidence of liver abscesses caused by <i>Fusobacterium necrophorum</i> and <i>Arcanobacterium</i> (<i>Actinomyces</i>) <i>pyogenes</i> in cattle fed in confinement for slaughter for the last 20 to 40 days on feed.",
"limitationText": "<p>Feed continuously during the last 20 to 40 days on feed. Do not allow horses or other equines access to feed containing monensin. Ingestion of monensin by horses has been fatal. Monensin medicated cattle feed is safe for use in cattle only. Consumption by unapproved species may result in toxic reactions. Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result. If feed refusals containing monensin are fed to other groups of cattle, the concentration of monensin in the refusals and amount of refusals fed should be taken into consideration to prevent monensin overdosing. Do not use in any finished feed (supplement, concentrate or complete feed) containing in excess of 2% bentonite.Zilpaterol hydrochloride is not for use in animals intended for breeding. Do not allow horses or other equines access to feed containing zilpaterol. Do not use in veal calves. Animals receiving zilpaterol hydrochloride may exhibit increased respiratory rate aswell as elevated levels of creatine phosphokinase (CPK) and creatine.Special considerations:1) Labeling for Type B feeds used to manufacture Type C complete feeds must bear the caution statement: Not to be fed to cattle in excess of 90 mg/head/day in complete feed. If pen consumption of complete feed exceeds 26.5 lb/head/day (90 percent dry matter basis), zilpaterol should not be fed in complete feed.</p><p>2) Type B Liquid Feeds can be manufactured containing 68 to 680 g zilpaterol hydrochloride/ton. Inadequate mixing (recirculation or agitation) of monensin liquid Type B or Type C medicated feeds has resulted in increased monensin concentration, which has been fatal to cattle. For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for not less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used. For liquid feeds stored in mechanical, air or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.3) All labeling for Type B and Type C feeds provides the warning: The active ingredient in Zilmax® is zilpaterol hydrochloride, a beta2-adrenergic agonist. Not for use in humans. An anti-dust process has been applied to the drug product, Zilmax®, in order to greatly reduce inhalation risk. Extended handling tasks with the potential for dust generation require respiratory protection. Wear appropriate skin protection (e.g., impervious gloves, apron, overalls), if there is a potential for extended skin contact. Wear protective eyewear, if there is a potential for eye contact. If accidental eye contact occurs, immediately rinse with water and consult a physician.<br/></p>",
"populationText": "Cattle (fed in confinement for slaughter)"
},
{
"indicationText": "For increased rate of weight gain, improved feed efficiency, increased carcass leanness, prevention and control of coccidiosis due to <i>Eimeria bovis</i> and <i>E. zuernii</i>, and reduction of incidence of liver abscesses caused by <i>Fusobacterium necrophorum</i> and <i>Arcanobacterium</i> (<i>Actinomyces</i>) <i>pyogenes</i> in cattle fed in confinement for slaughter for the last 20 to 40 days on feed.",
"limitationText": "<p>Feed continuously as sole ration during the last 20 to 40 days on feed. Do not allow horses or other equines access to feedscontaining monensin. Ingestion of monensin by horses has been fatal. Monensin medicated cattle feed is safe for use in cattle only. Consumption by unapproved species may result in toxic reactions. Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result. If feed refusals containing monensin are fed to other groups of cattle, the concentration of monensin in the refusals and amount of refusals fed should be taken into consideration to prevent monensin overdosing. Do not use in any finished feed (supplement, concentrate or complete feed) containing in excess of 2% bentonite.Zilpaterol hydrochloride is not for use in animals intended for breeding. Do not allow horses or other equines access to feed containing zilpaterol. Do not use in veal calves. Not to be fed to cattle in excess of 90 mg/head/day in complete feed. If pen consumption of complete feed exceeds 26.5 lb/head/day (90 percent dry matter basis), zilpaterol should not be fed in complete feed. Animals receiving zilpaterol hydrochloride may exhibit increased respiratory rate as well as elevated levels of creatine phosphokinase (CPK) and creatine.</p>",
"populationText": "Cattle (fed in confinement for slaughter)"
}
],
"withdrawalPeriodsStatus": "reported-unparsed",
"publisherIdentityMeaning": "applicationId/proprietaryNameId are technical website keys; applicationNumber is a separate FDA application reference",
"nativeNoticeOfHearingDate": null,
"nativeApplicationStatusCode": "A",
"nativeVoluntaryWithdrawalDate": null
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=us" \
--data-urlencode "sourceId=us.fda.animal-drugs" \
--data-urlencode "id=us:fda:animaldrugs:185:232"